

23 May 2024

India | Equity Research | Q4FY24 results review

Strides Pharma Science

Pharma

Traction in US building up

Strides Pharma Science (Strides)'s Q4FY24 results were driven by the launch of gSuprep in the US and better traction in growth and access markets. US touched annual sales of USD 250mn in FY24 and management expects it to rise by 14-20% in FY25; it also aims to achieve sales of USD 400mn in the next three years. For FY25, management guides for 12-14% revenue growth and EBITDA between INR 9.5-10bn (margins of 20-22%). Strides has a strong launch pipeline for the US market in H2FY25, which will drive overall momentum. Stelis has commercialised its drug substance division in Q4FY24 and entered into a commercial service agreement for liraglutide with a customer, targeting launch in FY25E. We raise our earnings estimate by 24-30% for FY25/26. We upgrade the stock to **ADD** (from Hold) with a higher target price of INR 1,000 (INR 710 earlier), valuing the company at 16x FY26E earnings.

gSuprep launch in US & traction in EMs drives beat in margin

Revenues grew 9.9% YoY (4.5% QoQ) to INR 10.8bn (l-Sec: INR 11bn) driven by better traction in growth and access markets. Gross margins expanded 220bps YoY (220bps QoQ) to 61.6% led by improved product mix and easing of API costs. Consequently, EBITDA margins rose 540bps YoY (250bps QoQ) to 21.1% (l-sec: 20.1%). EBITDA grew 47.7% YoY to INR 2.3bn (l-Sec: INR 2.2bn) driven by operating leverage. Adjusting for a one-off charge of INR 81mn, PAT stood at INR 246mn (l-sec: INR 194mn).

Momentum building up across segments

US revenues fell 3.2% QoQ to USD 65mn due to a weak flu season; however, the impact was partially offset by the launch of Icosapent and Suprep Bowel kit. Strides aims to launch 20 products p.a., which will help it clock USD 285-300mn in FY25E and USD 400mn by FY27E. Other regulated markets sales dipped 1% YoY (+1.1% QoQ) to INR 3.3bn. Growth markets were up 40.5% YoY to INR 1.2bn. Access markets sales grew 13% YoY to INR 644mn.

Multiple opportunities arising for Stelis

Stelis recorded positive EBITDA for the first time in its history. Launch of liraglutide (GLP-1) by its customer and commercialisation of new drug substance division will likely drive growth in FY25E. The company will file application with NCLT for Onesource in Q1FY25. FY25E revenue of Onesource is likely to be between USD 175-190mn and EBITDA at USD 60-65mn.

Financial Summary

Y/E March (INR mn)	FY23A	FY24A	FY25E	FY26E
Net Revenue	36,884	40,511	46,108	50,780
EBITDA	4,302	7,433	9,083	10,512
EBITDA Margin (%)	11.7	18.3	19.7	20.7
Net Profit	(2,075)	396	4,458	5,739
EPS (INR)	(22.6)	4.3	48.5	62.4
EPS % Chg YoY	(24.8)	(119.1)	1,024.8	28.7
P/E (x)	(40.1)	(117.1)	18.5	14.4
EV/EBITDA (x)	25.3	13.9	11.1	9.2
RoCE (%)	(0.3)	5.9	14.4	14.5
RoE (%)	(9.1)	1.8	19.1	20.4

Abdulkader Puranwala

abdulkader.puranwala@icicisecurities.com
+91 22 6807 7339

Market Data

Market Cap (INR)	83bn
Market Cap (USD)	993mn
Bloomberg Code	STR IN
Reuters Code	SRID BO
52-week Range (INR)	920 /346
Free Float (%)	74.0
ADTV-3M (mn) (USD)	3.3

Price Performance (%)	3m	6m	12m
Absolute	11.4	84.8	151.3
Relative to Sensex	10.0	72.4	131.6

Earnings Revisions (%)	FY24E	FY25E
Revenue		
EBITDA		
EPS		

Previous Reports

31-01-2024: [Q3FY24 result review](#)26-09-2023: [Q2FY24 result review](#)

Upbeat guidance for FY25

Management aims to grow its revenue by 12-14% in FY25. US business is likely to clock sales between USD 285–300mn in FY25 while other segments will also grow. Gross margins are likely to range between 58–62% and EBITDA at USD 9.5–10bn in FY25. It aims to repay INR 5bn of debt and bring debt to EBITDA under 2x (2.7x in FY24). Capex for FY25 is likely to be in the range of ~INR 1.5–2bn.

Valuation and risks

Strides' Q4 results are expected to have been driven by the launch of Icosapent and Suprep Bowel kit (each USD 15–20mn p.a. sales opportunity); further, better performance in Africa branded and the tender business has driven operating leverage. The company aims to launch 60 products in the next three years, which will help it scale up US revenues to USD 400mn while cashflows and divestment had helped retire INR 3.1bn of debt in FY24 (net debt at INR 20.4bn at end-FY24); it will further repay INR 5bn through internal accruals in FY25E. Besides entry in the inhalation market and 505 (b) (2) products will drive growth beyond FY27E. Outlook for Stelis is improving with the launch of GLP-1, biologics lined up in FY25, the ramp-up is happening earlier than our expectation. Listing of Onesource is on track – it has received NOCs from stock exchanges and SEBI, and will be filing with NCLT in Q1FY25.

We raise our revenue estimates by 3.9%/7.7% for FY25/26 and profits by 29.6%/23.8% for the same period. We expect revenue/EBITDA/PAT CAGR of 12%/18.9%/281% over FY24–26E.

We like the recent strategic developments being carried out by management, in terms of operating efficiencies and capital controls, we believe it has been sufficiently factored into the stock price. We raise our recommendation to **ADD** (from *Hold*) with a higher target price of INR 1,000/share based on 16x FY26E earnings (14x FY26E earnings earlier). **Key downside risks:** Slowdown in US sales; and regulatory hurdles.

Exhibit 1: Q4FY24 financial performance

Particulars (INR mn)	Q4FY24	Q4FY23	YoY % Chg	Q3FY24	QoQ % Chg	FY24	FY23	YoY % Chg
Net Sales	10,840	9,864	9.9	10,377	4.5	40,511	36,884	9.8
Gross Profit	6,678	5,857	14.0	6,164	8.3	24,106	20,615	16.9
Gross margins (%)	61.6	59.4	220bps	59.4	220bps	59.5	55.9	360bps
EBITDA	2,297	1,556	47.7	1,938	18.5	7,433	4,302	72.8
EBITDA margins (%)	21.2	15.8	540bps	18.7	250bps	18.3	11.7	670bps
Other income	(135)	271	(149.9)	88	(254.7)	397	903	(56.0)
PBIDT	2,162	1,827	18.3	2,026	6.7	7,830	5,205	50.4
Depreciation	498	609	(18.3)	512	(2.9)	2,207	2,433	(9.3)
Interest	802	805	(0.4)	793	1.1	3,144	2,611	20.4
Extra ordinary income/ (exp.)	(81)	(73)		(101)	(19.8)	(1,890)	(170)	
Share of profit/loss of JV & asso.	(486)	(406)		(520)		(1,757)	(2,853)	
PBT	296	(67)	(541.6)	100	196.0	(1,169)	(2,862)	(59.1)
Tax	193	71		101	90.6	(316)	553	
Minority Interest & Discontd. Op.	(78)	(43)		(498)		(779)	(283)	
Reported PAT	182	(95)		497		(706)	(2,026)	
Adjusted PAT	246	56		572		396	(2,075)	


Source: I-Sec research, Company data

Exhibit 2: Segmental performance

Business segment (INR mn)	Q4FY24	Q4FY23	YoY % Chg	Q3FY24	QoQ % Chg	FY24	FY23	YoY % Chg
US	5,380	5,097	5.6	5,560	(3.2)	20,632	18,447	11.8
Other regulated markets	3,322	3,356	(1.0)	3,286	1.1	12,750	12,503	2.0
Growth Markets	1,238	881	40.5	1,053	17.6	4,186	3,256	28.6
Access Markets	644	570	13.0	490	31.4	2,987	3,123	(4.4)
US (USD mn)	65	63	3.7	67	(3.0)	250	232	7.9


Source: I-Sec research, Company data

Exhibit 3: gSuprep driving growth in US




Source: I-Sec research, Company data

Exhibit 4: Launches to drive US growth




Source: I-Sec research, Company data

Exhibit 5: Other regulatory market growth declined on a higher base




Source: I-Sec research, Company data

Exhibit 6: Other regulated market revenues to register at 6.5% CAGR over FY24–26E




Source: I-Sec research, Company data

Exhibit 7: Emerging markets drive overall growth




Source: I-Sec research, Company data

Exhibit 8: Revenue CAGR of 12% over FY24–26E




Source: I-Sec research, Company data

Exhibit 9: Gross margins improved 220bps YoY with easing of API costs and better product mix




Source: I-Sec research, Company data

Exhibit 10: Gross margin on an upward trajectory with better mix




Source: I-Sec research, Company data

Exhibit 11: EBITDA margin expanded 540bps YoY at 21.2%




Source: I-Sec research, Company data

Exhibit 12: EBITDA margin to expand 240bps to ~21% by FY26E




Source: I-Sec research, Company data

Exhibit 13: Adj. PAT stood at INR 246mn for the quarter



Source: I-Sec research, Company data

Exhibit 14: On course to improve profitability



Source: I-Sec research, Company data

Exhibit 15: Shareholding pattern

%	Sep'23	Dec'23	Mar'24
Promoters	27.8	27.4	27.4
Institutional investors	37.1	38.9	38.9
MFs and others	13.7	13.1	13.1
Insurance	4.5	4.5	4.5
FIIIs	18.9	21.3	21.3
Others	35.1	33.7	33.7

Source: Bloomberg

Exhibit 16: Price chart



Source: Bloomberg

Financial Summary

Exhibit 17: Profit & Loss

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Net Sales	36,884	40,511	46,108	50,780
Operating Expenses	16,313	16,674	18,581	20,211
EBITDA	4,302	7,433	9,083	10,512
EBITDA Margin (%)	11.7	18.3	19.7	20.7
Depreciation & Amortization	2,433	2,207	2,284	2,439
EBIT	1,869	5,226	6,800	8,073
Interest expenditure	2,611	3,144	1,913	1,713
Other Non-operating Income	903	397	405	413
Recurring PBT	161	2,478	5,291	6,772
Profit / (Loss) from Associates	(2,667)	(1,215)	(439)	(448)
Less: Taxes	(553)	316	631	822
PAT	544	272	4,660	5,950
Less: Minority Interest	97	237	237	237
Extraordinaries (Net)	-	-	-	-
Net Income (Reported)	(2,026)	(706)	4,458	5,739
Net Income (Adjusted)	(2,075)	396	4,458	5,739

Source Company data, I-Sec research

Exhibit 18: Balance sheet

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Total Current Assets	30,204	26,973	29,657	33,567
of which cash & cash eqv.	3,160	1,912	1,675	3,163
Total Current Liabilities & Provisions	13,041	11,055	12,408	13,493
Net Current Assets	17,163	15,918	17,249	20,074
Investments	4,515	2,088	2,088	2,088
Net Fixed Assets	11,397	7,892	7,608	7,169
ROU Assets	1,846	895	895	895
Capital Work-in-Progress	483	799	799	799
Total Intangible Assets	10,769	10,565	10,565	10,565
Other assets	4,941	5,969	6,002	6,030
Deferred Tax Assets	2,230	2,717	3,093	3,406
Total Assets	53,343	47,342	48,868	51,653
Liabilities				
Borrowings	27,745	24,145	21,645	19,145
Deferred Tax Liability	446	403	403	403
provisions	734	916	1,043	1,149
other Liabilities	139	137	137	137
Equity Share Capital	903	919	919	919
Reserves & Surplus	20,826	19,798	23,697	28,877
Total Net Worth	21,729	20,717	24,616	29,796
Minority Interest	-	-	-	-
Total Liabilities	53,343	47,342	48,868	51,653

Source Company data, I-Sec research

Exhibit 19: Cashflow statement

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Operating Cashflow	444	7,011	6,499	8,024
Working Capital Changes	2,611	3,144	1,913	1,713
Capital Commitments	(2,265)	(1,107)	(2,000)	(2,000)
Free Cashflow	2,709	8,118	8,499	10,024
Other investing cashflow	5,290	(395)	-	-
Cashflow from Investing Activities	3,025	(1,503)	(2,000)	(2,000)
Issue of Share Capital	14	14	-	-
Interest Cost	(2,611)	(3,144)	(1,913)	(1,713)
Inc (Dec) in Borrowings	-	-	-	-
Dividend paid	-	-	(322)	(322)
Others	459	(3,803)	(2,500)	(2,500)
Cash flow from Financing Activities	(2,139)	(6,933)	(4,736)	(4,536)
Chg. in Cash & Bank balance	1,330	(1,425)	(237)	1,488
Closing cash & balance	3,203	1,735	1,675	3,163

Source Company data, I-Sec research

Exhibit 20: Key ratios

(Year ending March)

	FY23A	FY24A	FY25E	FY26E
Per Share Data (INR)				
Reported EPS	(22.4)	(7.7)	48.5	62.4
Adjusted EPS (Diluted)	(22.6)	4.3	48.5	62.4
Cash EPS	4.0	28.3	73.4	89.0
Dividend per share (DPS)	3.6	3.5	3.5	3.5
Book Value per share (BV)	240.7	231.3	276.3	335.2
Dividend Payout (%)	(15.9)	(45.6)	7.2	5.6
Growth (%)				
Net Sales	20.1	9.8	13.8	10.1
EBITDA	(4,267.5)	72.8	22.2	15.7
EPS (INR)	(24.8)	(119.1)	1,024.8	28.7
Valuation Ratios (x)				
P/E	(40.1)	(117.1)	18.5	14.4
P/CEPS	227.0	31.8	12.3	10.1
P/BV	3.7	3.9	3.3	2.7
EV / EBITDA	25.3	13.9	11.1	9.2
P / Sales	2.2	2.0	1.8	1.6
Dividend Yield (%)	0.0	0.0	0.0	0.0
Operating Ratios				
Gross Profit Margins (%)	55.9	59.5	60.0	60.5
EBITDA Margins (%)	11.7	18.3	19.7	20.7
Effective Tax Rate (%)	5,965.6	53.7	11.9	12.1
Net Profit Margins (%)	(5.6)	1.0	9.7	11.3
NWC / Total Assets (%)	-	-	-	-
Net Debt / Equity (x)	0.9	1.0	0.7	0.5
Net Debt / EBITDA (x)	4.7	2.7	2.0	1.3
Profitability Ratios				
RoCE (%)	(0.3)	5.9	14.4	14.5
RoE (%)	(9.1)	1.8	19.1	20.4
RoC (%)	(1.1)	5.4	13.8	14.5
Fixed Asset Turnover (x)	3.0	4.2	5.9	6.9
Inventory Turnover Days	124	106	106	103
Receivables Days	140	108	110	108
Payables Days	106	80	81	78

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Abdulkader Puranwala, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Prabodh Avadhoot](#) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
